Last reviewed · How we verify
Cisplatin+Vindesine+MMC/ concurrent radiation
This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms.
This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms. Used for Locally advanced non-small cell lung cancer (concurrent chemoradiation).
At a glance
| Generic name | Cisplatin+Vindesine+MMC/ concurrent radiation |
|---|---|
| Sponsor | West Japan Thoracic Oncology Group |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that cross-links DNA; vindesine is a vinca alkaloid that disrupts microtubule formation during mitosis; and mitomycin C is an antibiotic that alkylates DNA. When combined with concurrent radiation therapy, these agents work synergistically to maximize tumor cell death in locally advanced cancers.
Approved indications
- Locally advanced non-small cell lung cancer (concurrent chemoradiation)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Esophagitis
- Pneumonitis
- Nephrotoxicity
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: